Isaac W. Boss

1.9k total citations
29 papers, 1.1k citations indexed

About

Isaac W. Boss is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Isaac W. Boss has authored 29 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 12 papers in Molecular Biology and 9 papers in Oncology. Recurrent topics in Isaac W. Boss's work include Acute Myeloid Leukemia Research (8 papers), CAR-T cell therapy research (7 papers) and Multiple Myeloma Research and Treatments (5 papers). Isaac W. Boss is often cited by papers focused on Acute Myeloid Leukemia Research (8 papers), CAR-T cell therapy research (7 papers) and Multiple Myeloma Research and Treatments (5 papers). Isaac W. Boss collaborates with scholars based in United States, Spain and Germany. Isaac W. Boss's co-authors include Rolf Renne, María López, Henry V. Baker, Mark A. Samols, Rebecca L. Skalsky, Alberto Riva, Yajie Yang, Jeffrey R. Abbott, Ayalew Mergia and Ari Melnick and has published in prestigious journals such as Blood, Cancer Research and Journal of Virology.

In The Last Decade

Isaac W. Boss

25 papers receiving 1.1k citations

Peers

Countries citing papers authored by Isaac W. Boss

Since Specialization

Citations

This map shows the geographic impact of Isaac W. Boss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isaac W. Boss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isaac W. Boss more than expected).

Fields of papers citing papers by Isaac W. Boss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isaac W. Boss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isaac W. Boss. The network helps show where Isaac W. Boss may publish in the future.

Co-authorship network of co-authors of Isaac W. Boss

This figure shows the co-authorship network connecting the top 25 collaborators of Isaac W. Boss. A scholar is included among the top collaborators of Isaac W. Boss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isaac W. Boss. Isaac W. Boss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab 2025 ·Therapeutic Advances in Hematology ·Jan Philipp Bewersdorf, (unknown), Rory M. Shallis, Ethan Thompson, Daniel L. Menezes, Shelonitda Rose, Isaac W. Boss, Lourdes Mendez, Nikolai A. Podoltsev, Maximilian Stahl, Tariq Kewan, Stephanie Halene, Torsten Haferlach, Brian A. Fox, Amer M. Zeidan	0
2	Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine 2024 ·Therapeutic Advances in Hematology ·Amer M. Zeidan, Jan Philipp Bewersdorf, (unknown), Rory M. Shallis, Ethan Thompson, Daniel L. Menezes, (unknown), Isaac W. Boss, Stephanie Halene, Torsten Haferlach, Brian A. Fox	8
3	P799: SYNERGISTIC ANTITUMOR ACTIVITY OF THE BCMA 2 + 1 T CELL ENGAGER (TCE) ALNUCTAMAB (ALNUC; BMS-986349; CC-93269) AND CELMOD AGENTS IN MULTIPLE MYELOMA (MM) PRECLINICAL MODELS 2023 ·HemaSphere ·Bruno Paiva, (unknown), (unknown), Paola Castiglioni, (unknown), Daniel W. Pierce, Isaac W. Boss	0
4	Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy 2022 ·Leukemia ·Amer M. Zeidan, Jan Philipp Bewersdorf, (unknown), Rory M. Shallis, Ethan Thompson, Daniel L. Menezes, (unknown), Isaac W. Boss, Stephanie Halene, Torsten Haferlach, Brian A. Fox	10
5	Suppression of Myeloid Cell-Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs) 2022 ·Blood ·Danny V. Jeyaraju, (unknown), (unknown), (unknown), Isaac W. Boss, Patrick R. Hagner, Michael Pourdehnad, Michael R. Burgess, William E. Pierceall, Anjan Thakurta	6
6	Molecular, Epigenetic, and Immune Landscape of TP53-mutated (TP53-M) Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS) 2022 ·Blood ·Jan Philipp Bewersdorf, (unknown), Rory M. Shallis, Ethan Thompson, Daniel L. Menezes, Shelonitda Rose, Isaac W. Boss, Stephanie Halene, Torsten Haferlach, Brian A. Fox, Amer M. Zeidan	2
7	Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) 2022 ·Blood ·Isaac W. Boss, Ethan Thompson, Allison Gaudy, Minh Diem Vu, Colin D. Godwin, Michael R. Burgess, Sandy W. Wong, Luciano J. Costa	4
8	A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML 2021 ·Blood Advances ·Amer M. Zeidan, Isaac W. Boss, C.L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, (unknown), Andrzej Hellmann, David Taussig, Mar Tormo, Maria Teresa Voso, James D. Cavenagh, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Lewis R. Silverman	64
9	Immune and Epigenetic Landscape of TP53-mutated Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) 2021 ·Blood ·Amer M. Zeidan, Jan Philipp Bewersdorf, (unknown), Ethan Thompson, Daniel L. Menezes, Shelonitda Rose, Isaac W. Boss, Brian A. Fox	2
10	First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial 2019 ·Blood ·Luciano J. Costa, Sandy W. Wong, Arancha Bermúdez, Javier de la Rubia, María‐Victoria Mateos, Enrique M. Ocio, Paula Rodríguez‐Otero, Jesús F. San Miguel, Shaoyi Li, R. Sarmiento, Pilar Lardelli, Allison Gaudy, Isaac W. Boss, Lisa M. Kelly, Michael R. Burgess, Kristen Hege, William Bensinger	132
11	Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study 2019 ·Blood ·Amer M. Zeidan, James D. Cavenagh, Maria Teresa Voso, David Taussig, Mar Tormo, Isaac W. Boss, Wilbert B. Copeland, Vanessa E. Gray, Alessandro Previtali, (unknown), Shelonitda Rose, C.L. Beach, Lewis R. Silverman	60
12	A systems biology approach identified different regulatory networks targeted by KSHV miR-K12-11 in B cells and endothelial cells 2014 ·BMC Genomics ·Yajie Yang, Isaac W. Boss, Lauren M. McIntyre, Rolf Renne	8
13	KSHV miRNAs Decrease Expression of Lytic Genes in Latently Infected PEL and Endothelial Cells by Targeting Host Transcription Factors 2014 ·Viruses ·(unknown), (unknown), (unknown), Brian J. Krueger, Isaac W. Boss, Lauren A. Gay, (unknown), Jianhong Hu, Rolf Renne	36
14	A Kaposi's Sarcoma-Associated Herpesvirus-Encoded Ortholog of MicroRNA miR-155 Induces Human Splenic B-Cell Expansion in NOD/LtSz-scid IL2Rγ ^null Mice 2011 ·Journal of Virology ·Isaac W. Boss, (unknown), Jeffrey R. Abbott, Yajie Yang, Ayalew Mergia, Rolf Renne	99
15	A KSHV encoded ortholog of miR-155 induces human splenic B-cell expansion in NOD/LtSz-scid IL2R{gamma}null mice 2011 ·Isaac W. Boss, (unknown), J. Richard Abbott, Yajie Yang, Ayalew Mergia, Rolf Renne	3
16	Viral miRNAs and immune evasion 2011 ·Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms ·Isaac W. Boss, Rolf Renne	62
17	Viral miRNAs: tools for immune evasion 2010 ·Current Opinion in Microbiology ·Isaac W. Boss, Rolf Renne	56
18	Role of virus-encoded microRNAs in herpesvirus biology 2009 ·Trends in Microbiology ·Isaac W. Boss, (unknown), Rolf Renne	92
19	Kaposi's Sarcoma-Associated Herpesvirus Encodes an Ortholog of miR-155 2007 ·Journal of Virology ·Rebecca L. Skalsky, Mark A. Samols, (unknown), Isaac W. Boss, Alberto Riva, María López, Henry V. Baker, Rolf Renne	360
20	A comparison between intranasal budesonide aerosol and budesonide dry powder in the treatment of hay fever symptoms. 1991 ·PubMed ·Henrik Malmberg, Elina Holopainen, Markku Simola, Isaac W. Boss, N. Lindqvist	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact